Valuation: Vaxart, Inc.

Market Cap 106M 94.43M 88.13M 80.33M 152M 10.22B 153M 1.07B 413M 5.22B 399M 390M 16.76B P/E 2026 *
-2.73x
P/E 2027 * -0.51x
Enterprise Value 106M 94.43M 88.13M 80.33M 152M 10.22B 153M 1.07B 413M 5.22B 399M 390M 16.76B EV / Sales 2026 *
0.9x
EV / Sales 2027 * 45.2x
Free-Float
98.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.68%
1 week-3.92%
Current month-2.89%
1 month-11.27%
3 months-31.72%
6 months-28.36%
Current year+26.15%
1 week 0.43
Extreme 0.43
0.47
1 month 0.43
Extreme 0.43
0.52
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
8.13
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 2024-03-17
Chief Tech/Sci/R&D Officer 59 2024-02-29
Director of Finance/CFO - 2025-05-18
Director TitleAgeSince
Director/Board Member 68 2021-04-20
Director/Board Member 76 2022-08-03
Director/Board Member 79 2021-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/16/26 Free

Director

118,100 0.0488%
7/16/26 Free

Director

118,100 0.0488%
7/16/26 Free

Director

118,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
-0.68%-3.92%+20.55%-38.54% 106M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.27%-0.92%+49.43%+111.83% 39.06B
Weighted average by Cap. +0.12%-0.84%+56.95%+138.21%

Financials

2026 *2027 *
Net sales 119M 105M 98.35M 89.64M 169M 11.4B 171M 1.19B 461M 5.83B 445M 436M 18.71B 2.35M 2.09M 1.95M 1.78M 3.35M 226M 3.38M 23.58M 9.14M 115M 8.82M 8.63M 371M
Net income -47.2M -41.94M -39.14M -35.68M -67.29M -4.54B -67.91M -474M -184M -2.32B -177M -173M -7.44B -222M -197M -184M -167M -316M -21.3B -319M -2.22B -862M -10.89B -832M -814M -34.95B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
26-10-02 US$0.4370 -0.68% 239,377
26-10-01 US$0.4400 -2.22% 339,926
26-09-30 US$0.4500 -0.04% 161,720
26-09-29 US$0.4502 -1.66% 297,712
26-09-28 US$0.4578 +0.64% 124,977
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.4370USD
Average target price
3.333USD
Spread / Average Target
+662.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock